Gavreto wins conditional EU approval to treat form of lung cancer -Roche (updated)

CStone Pharmaceuticals

19/11/2021 14:47

(Adds Roche partners)
    ZURICH, Nov 19 (Reuters) - Roche's  ROG.S  Gavreto has won
conditional European Commission approval for treating adults
with a form of non-small cell lung cancer, the Swiss drugmaker
said on Friday.
    Gavreto, known generically as pralsetinib, is the first and
only precision medicine approved in the EU for first-line
treatment of people with RET fusion-positive advanced NSCLC.
Around 37,500 people are diagnosed with RET fusion-positive
NSCLC worldwide each year, it said https://www.roche.com/media/releases/med-cor-2021-11-19.htm
 in a statement.
    Blueprint Medicines  BPMC.O  and Roche are co-developing
Gavreto globally, with the exception of certain territories in
Asia, including China.
    Blueprint Medicines and Roche unit Genentech are
commercialising Gavreto in the United States, and Roche has
exclusive commercialisation rights for Gavreto outside the
United States, with the exception of some parts of Asia.
    CStone Pharmaceuticals  2616.HK  retains rights to the
development and commercialisation of Gavreto in mainland China,
Taiwan, Hong Kong and Macau under an collaboration accord with
Blueprint Medicines, Roche said.

 (Reporting by Michael Shields
Editing by Riham Alkousaa and Steve Orlofsky)
 ((Michael.Shields@thomsonreuters.com; +41 41 528 3630; Reuters
Messaging: michael.shields.thomsonreuters.com@reuters.net))